E

    Entera Bio Ltd (ENTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.95
    -0.08 (-2.64%)

    Market Cap: $524.62M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(22/32)
    Avg Surprise
    -6.57%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.08
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.20-150.0%
    60d ago$-0.20-150.0%
    30d ago$-0.08+0.0%
    7d ago$-0.08+0.0%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.10 - $-0.10
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.08---
    Jun 26
    		$-0.14$-0.08-75.00%Miss-133.3%
    Mar 26
    		$-0.07$-0.08+12.50%Beat-16.7%
    Dec 25
    		$-0.06$-0.11+45.45%Beat+0.0%
    Sep 25
    		$-0.07$-0.09+22.22%Beat+12.5%
    Jun 25
    		$-0.06$-0.11+45.45%Beat+0.0%
    Mar 25
    		$-0.06$-0.07+14.29%Beat-20.0%
    Dec 24
    		$-0.06$-0.08+25.00%Beat+14.3%
    Sep 24
    		$-0.08$-0.05-60.00%Miss+0.0%
    Jun 24
    		$-0.06$-0.06+0.00%Beat+25.0%
    Mar 24
    		$-0.05$-0.06+16.67%Beat+37.5%
    Dec 23
    		$-0.07$-0.08+12.50%Beat+30.0%
    Sep 23
    		$-0.08$-0.09+11.11%Beat+27.3%
    Jun 23
    		$-0.08$-0.07-14.29%Miss+27.3%
    Mar 23
    		$-0.08$-0.12+33.33%Beat+38.5%
    Dec 22
    		$-0.10$-0.11+9.09%Beat+52.4%
    Sep 22
    		$-0.11$-0.13+15.38%Beat-120.0%
    Jun 22
    		$-0.11$-0.16+31.25%Beat+47.6%
    Mar 22
    		$-0.13$-0.18+27.78%Beat+69.8%
    Dec 21
    		$-0.21$-0.23+8.70%Beat-61.5%
    Sep 21
    		$-0.05N/A+54.55%Beat+44.4%
    Jun 21
    		$-0.21$-0.12-75.00%Miss-23.5%
    Mar 21
    		$-0.43$-0.12-258.33%Miss-368.7%
    Dec 20
    		$-0.13$-0.14+7.14%Beat+50.0%
    Sep 20
    		$-0.09N/A+55.00%Beat+64.0%
    Jun 20
    		$-0.17$-0.12-41.67%Miss-41.7%
    Mar 20
    		$0.16$0.00N/ABeat+161.5%
    Dec 19
    		$-0.26$-0.19-36.84%Miss-52.9%
    Sep 19
    		$-0.25$-0.15-66.67%Miss+44.4%
    Jun 19
    		$-0.12N/A+57.14%Beat+25.0%
    Mar 19
    		$-0.26$0.00N/ABeat-225.0%
    Dec 18
    		$-0.17N/A+51.43%Beat+45.2%
    Sep 18
    		$-0.45$-0.28-60.71%Miss-136.8%
    Jun 18
    		$-0.16$-0.09-77.78%Miss-23.1%
    Mar 18
    		$-0.08$-0.08+0.00%Beat-14.3%
    Dec 17
    		$-0.31$0.00N/AMiss-106.7%
    Sep 17
    		$-0.19$0.00N/AMiss-
    Mar 17
    		$-0.13$0.00N/AMiss-
    Dec 16
    		$-0.07$0.00N/AMiss-
    Sep 16
    		$-0.15$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.68EV/EBITDA-1.52x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-138.90%ROIC-173.65%
    Financial Health
    Debt/Equity0.07xInterest CoverageN/A
    Current Ratio8.98xQuick Ratio8.98x
    Trading Statistics
    Beta1.40Avg Volume429.22K
    52-Week High$4.2052-Week Low$0.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.16
    SMA 20$3.02
    SMA 50$2.43
    SMA 200$1.74
    EMA 10$3.10
    EMA 20$2.99
    EMA 50$2.54
    EMA 200$1.93

    MACD

    Line: 0.19Signal: 0.24Hist: -0.05

    ADX

    ADX: 49.4+DI: 24.3-DI: 16.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down40.0
    PSAR$2.61

    Bollinger Bands

    Upper Band$3.42
    Lower Band$2.63
    %B Position2613%(Upper)
    Band Width0.41

    RSI (14-Day)

    Neutral
    52.3

    Momentum Oscillators

    Stoch %K35.3
    Stoch %D49.1
    Williams %R-75.3
    ROC (10d)1.7%
    Momentum0.05
    CCI (20d)-14.0
    MFI (14d)59.6

    Volatility Measures

    ATR (14d)$0.27(9.1%)
    StdDev (20d)0.20
    Hist Vol63.0%(High)

    Volume Flow

    VWAP$2.98
    OBV132.3M
    AD Line7.7M
    CMF (20d)0.093

    Volume Metrics

    Avg Vol (20d)395.6K
    Vol Ratio0.5x
    VWMA (20d)$3.03

    Pivot Points

    R3$3.27
    R2$3.21
    R1$3.12
    Pivot Point$3.06
    S1$2.97
    S2$2.91
    S3$2.82

    Advanced Oscillators

    TSI21.27
    Ultimate Osc40.5
    KST395.70

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$42,000$82,000$42,000$57,000$0$4.48M$0
    Cost of Revenue$0$0$7,000$0$0$42,000$82,000$42,000$48,000$0$13,000$0
    Gross Profit$0$0$-7,000$0$0$0$0$0$9,000$0$-13,000$0
    Operating Expenses$4.56M$3.54M$3.04M$3.26M$2.67M$2.56M$2.34M$3.02M$2.17M$2.06M$1.94M$2.39M
    R&D$3.20M$2.25M$1.72M$1.64M$1.52M$1.12M$1.20M$1.48M$1.09M$735,000$1.00M$1.37M
    SG&A$1.36M$1.29M$1.32M$1.61M$1.15M$1.44M$1.14M$1.54M$1.09M$1.33M$973,000$1.03M
    Operating Income$-4,563,000$-3,539,000$-3,042,000$-3,256,000$-2,668,000$-2,563,000$-2,337,000$-3,021,000$-2,165,000$-2,062,000$-1,963,000$-2,386,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2.75M$0$0$0$0$4,000$7,000$0$0$0$32,000$0
    Income Before Tax$-7,312,000$-3,505,000$-3,016,000$-3,200,000$-2,656,000$-2,567,000$-2,344,000$-3,021,000$-2,145,000$-2,017,000$-1,995,000$-2,350,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$29,000
    Net Income$-7,312,000$-3,505,000$-3,016,000$-3,200,000$-2,656,000$-2,567,000$-2,358,000$-3,021,000$-2,145,000$-2,017,000$-1,995,000$-2,379,000
    EBITDA$-7,303,000$-3,498,000$-3,009,000$-3,192,000$-2,649,000$-2,559,000$-2,333,000$-3,010,000$-2,134,000$-2,004,000$-1,982,000$-2,336,000
    EBIT$-7,312,000$-3,505,000$-3,016,000$-3,200,000$-2,656,000$-2,567,000$-2,344,000$-3,021,000$-2,145,000$-2,017,000$-1,995,000$-2,350,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENTX

    News

    Entera Bio raises $275M in oversubscribed placement, shares rebound on funding news

    Entera Bio Ltd. (NASDAQ: ENTX) has successfully raised $275 million through an oversubscribed private placement, primarily to fund Phase 3 trials for its osteoporosis drug candidate, EB613. This capital injection is expected to extend the company's cash runway into 2030 and was led by existing investor BVF Partners. Despite potential dilution, the news led to a rebound in share prices, reflecting strong institutional confidence in EB613's commercial potential.

    scanx.trade•8/23/26•
    Bullish

    Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1% - Here's Why

    Entera Bio (NASDAQ:ENTX) saw its stock price increase by 5.1% to $3.27, although trading volume was significantly lower than average. Analyst sentiment is mixed, with a consensus "Hold" rating and a target price of $9.00. The company reported a quarterly loss of $0.14 per share, missing the consensus estimate, and institutional investors collectively own 14.11% of the stock.

    MarketBeat•8/20/26•
    Neutral

    Entera Bio appoints new chief medical officer

    Entera Bio (ENTX) has appointed Riccardo Paolo Camisasca, M.D., as its new Chief Medical Officer, a strategic move to bolster its clinical execution capabilities ahead of the planned Phase 3 initiation for EB613, its lead oral anabolic osteoporosis candidate. Camisasca brings over three decades of pharmaceutical experience, including extensive work in clinical development, regulatory strategy, and R&D leadership. This appointment is expected to support the company's efforts to advance its oral peptide platform into commercially viable therapies.

    The Globe and Mail•8/19/26•
    Somewhat-Bullish

    Form 8K Entera Bio Ltd. For: 18 August By Investing.com

    This article announces that Entera Bio Ltd. has filed a Form 8K on August 18. It is a very brief notification from Investing.com, providing no further details about the content of the filing. The article also includes various market data and related news headlines.

    Investing.com Nigeria•8/19/26•
    Neutral

    Form 8K Entera Bio Ltd. For: 18 August By Investing.com

    This article reports on the filing of Form 8K by Entera Bio Ltd. for August 18th. The news briefly mentions the company and its stock symbol ENTX, along with its current stock performance. It is a concise update about a regulatory filing.

    Investing.com Canada•8/19/26•
    Neutral

    Frequently Asked Questions About ENTX

    Does ENTX pay dividends?
    Entera Bio Ltd (ENTX) does not currently pay a regular dividend.
    What is ENTX's market cap?
    Entera Bio Ltd (ENTX) has a market capitalization of $524.62M with a current stock price of $2.95.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In